Charles River Laboratories International (CRL) Retained Earnings (2009 - 2026)
Charles River Laboratories International (CRL) posted Retained Earnings of $1.4 billion for Q2 2026, little changed on a QoQ basis from $1.4 billion in Q1 2026, and down 27.39% year-over-year from $1.9 billion in Q2 2025.
Analysis
Charles River Laboratories International (CRL) Retained Earnings (2009 - 2026) Analysis & Trends
Charles River Laboratories International has reported Retained Earnings for 18 years, with the latest figure at $1.4 billion in Q2 2026.
- On a quarterly basis, Retained Earnings fell 27.39% year-over-year to $1.4 billion in Q2 2026; TTM through Jun 2026 was $1.4 billion, a 27.39% decrease from a year earlier, with the FY2025 full-year figure at $1.4 billion, down 23.37% from the prior year.
- Retained Earnings was $1.4 billion for Q2 2026 at Charles River Laboratories International, roughly flat from $1.4 billion in the prior quarter.
- The five-year high for Retained Earnings was $2.1 billion in Q3 2024, with the low at $1.1 billion in Q1 2022.
- Average Retained Earnings over 5 years is $1.6 billion, with a median of $1.7 billion recorded in 2023.
- The sharpest annual moves came in 2022 and 2026: Retained Earnings jumped 56.31% in 2022, then declined 27.39% in 2026.
- Over 5 years, Retained Earnings stood at $1.4 billion in 2022, then surged by 31.71% to $1.9 billion in 2023, then retreated by 3.98% to $1.8 billion in 2024, then fell by 23.37% to $1.4 billion in 2025, then decreased by 1.18% to $1.4 billion in 2026.
- The last three Retained Earnings figures came in at $1.4 billion (Q2 2026), $1.4 billion (Q1 2026), and $1.4 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn | 7.96 Bn |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn | -511.37 Mn |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn | 2.30 Bn |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn | 1.37 Bn |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn | 2.14 Bn |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - | 1.71 Bn |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn | 6.70 Bn |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn | -81.50 Mn |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn | -106.74 Mn |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - | -357.34 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 27, 2026 | 1.37 Bn |
| Mar 28, 2026 | 1.37 Bn |
| Dec 27, 2025 | 1.39 Bn |
| Sep 27, 2025 | 1.94 Bn |
| Jun 28, 2025 | 1.89 Bn |
| Mar 29, 2025 | 1.84 Bn |
| Dec 28, 2024 | 1.81 Bn |
| Sep 28, 2024 | 2.12 Bn |
| Jun 29, 2024 | 2.05 Bn |
| Mar 30, 2024 | 1.96 Bn |
| Dec 30, 2023 | 1.89 Bn |
| Sep 30, 2023 | 1.72 Bn |
| Jul 1, 2023 | 1.63 Bn |
| Apr 1, 2023 | 1.54 Bn |
| Dec 31, 2022 | 1.43 Bn |
| Sep 24, 2022 | 1.28 Bn |
| Jun 25, 2022 | 1.18 Bn |
| Mar 26, 2022 | 1.07 Bn |
| Dec 25, 2021 | 980.75 Mn |
| Sep 25, 2021 | 878.82 Mn |